E
E.V.A Biosystems
Using synthetic biology to develop new bioplastics for manufacturing
About E.V.A Biosystems
E.V.A Biosystems, based in Edinburgh, is a forward-thinking startup focused on using synthetic biology to create new types of bioplastics. Founded in 2021 by Dr. Alexander Speakman, the company aims to address the global issue of plastic pollution while maintaining the beneficial properties that make plastic so essential in modern life. The company operates in the bioplastics market, which is a niche within the broader materials and manufacturing industry.
E.V.A Biosystems primarily serves manufacturers who are looking for sustainable alternatives to traditional plastics. These clients could range from packaging companies to consumer goods manufacturers, essentially any business that relies on plastic materials but wants to reduce its environmental footprint.
The business model of E.V.A Biosystems revolves around research and development (R&D) to create innovative bioplastic solutions. They are currently seeking investors to fund their ongoing R&D efforts and to help bring their first products to market. Once their bioplastics are ready for commercial use, the company plans to generate revenue by selling these materials to manufacturers or licensing their technology to other companies.
In summary, E.V.A Biosystems is tackling the pressing issue of plastic pollution by developing sustainable bioplastics through advanced synthetic biology. They are in the early stages of growth and are actively seeking investment to support their mission.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Edinburgh, United Kingdom
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 64.0/100
- Industry
- Energy
- Sub-industry
- Waste Solution
- Sector
- Energy, Biotechnology, Plastic, Waste Reduction, Sustainable Development Goals, Bioplastic, Plastic Pollution, Climate Tech, Circular Economy, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | May 2025 | $371K | — | UK Research and Innovation | — |
Growth signals
Latest recorded traffic for E.V.A Biosystems is 640 monthly website visits, up 300% over the last three months. E.V.A Biosystems's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
UK Research and Innovation
Other known investors2 additional known investors
Scottish EDGE
Techscaler
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about E.V.A Biosystems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See E.V.A Biosystems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







